At Gilead, we are dedicated to advancing the care of patients suffering from life-threatening diseases worldwide. Our research and development effort is the largest it has ever been, with more than 200 active clinical studies evaluating compounds with potential to become next-generation therapies. Collaboration with other companies, universities and medical research institutions enhance our ability to discover and develop innovative new medicines.

Our goal is to improve HIV care by developing new single tablet regimens – with one pill once a day, eligible patients take all of their medication in each dose, which increases dosing convenience and potentially reduces the risk of drug resistance. Gilead scientists are also engaged in early-stage research to identify novel therapeutic agents that may help eradicate HIV infection.

HIV / AIDS

Phase 1
Phase 2
Phase 3

Cobicistat (pharmacokinetic enhancer)
Potential Indication: HIV/AIDS

EU approval as Tybost®; U.S. Regulatory Submission

Elvitegravir (integrase inhibitor)
Potential Indication: HIV/AIDS

EU Approval as Vitekta® , U.S. Regulatory Submissions

Single Tablet Regimen (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
Potential Indication: HIV/AIDS

Single Tablet Regimen
(darunavir/cobicistat/emtricitabine/tenofovir alafenamide)
Potential Indication: HIV/AIDS

Our liver disease research focuses on new treatment options for chronic hepatitis B and C. For hepatitis B, we continue to research approaches to increase cure rates, including oral medicines and therapeutic vaccines. For hepatitis C, we are working to develop an all-oral regimen that results in higher cure rates over a shortened treatment duration compared to today’s standard of care.

Liver Diseases

Phase 1
Phase 2
Phase 3

Fixed-Dose Combination of ledipasvir and sofosbuvir  (NS5A inhibitor/nucleotide NS5B inhibitor)
Potential indication: Chronic HCV infection

U.S. and EU Regulatory Submissions

Fixed-Dose Combination of sofosbuvir and GS-5816 (pan-genotypic NS5B/NS5A inhibitors)
Potential indication: Chronic HCV infection

GS-9451 (NS3 protease inhibitor)
Potential Indication: Chronic HCV infection

GS-9669 (non-nucleoside NS5B site 2 polymerase inhibitor)
Potential Indication: Chronic HCV infection

GS-9620 (TLR-7 agonist)
Potential Indication: Chronic HCV infection

GS-9857 (pan-genotypic NS3 protease inhibitor)
Potential Indication: Chronic HCV infection

Tenofovir Alafenamide (nucleotide reverse transcriptase inhibitor)
Potential Indication: Chronic HBV infection

GS-4774 (Tarmogen T cell immunity stimulator)
Potential Indication: Chronic HBV infection

GS-9620 (TLR-7 agonist)
Potential Indication: Chronic HBV infection

Simtuzumab (monoclonal antibody)
Potential Indication: Liver Fibrosis

GS-5745 (MMP9 mAb inhibitor)
Potential Indication: Ulcerative Colitis

A range of clinical studies are ongoing to explore new uses for Ranexa®, currently indicated for the treatment of chronic angina, that can potentially benefit a broader population of patients. We are also working to identify new therapies for cardiovascular disease by exploring the mechanism of action underlying Ranexa – inhibition of the late sodium current.

Cardiovascular

Phase 1
Phase 2
Phase 3

Ranolazine (late sodium current inhibitor)
Potential Indication: Incomplete Revascularization Post-PCI

Ranolazine (late sodium current inhibitor)
Potential Indication: Type 2 Diabetes

Ranolazine/Dronedarone Fixed-Dose Combination (late sodium current inhibitor)
Potential Indication: Paroxysmal Atrial Fibrillation

GS-6615 (late sodium current inhibitor)
Potential indication: Long QT-3 Syndrome

GS-6615 (late sodium current inhibitor)
Potential indication: Hypertrophic Cardiomyopathy

GS-6615 (late sodium current inhibitor)
Potential indication: Ventricular Tachycardia/Ventricular Fibrillation

GS-4997 (ASK-1 inhibitor)
Potential indication: Diabetic Nephropathy

Gilead is investigating new ways to improve care for people who suffer from potentially life-threatening respiratory disorders. Simtuzumab is being investigated for the potential treatment of idiopathic pulmonary fibrosis, a life-threatening scarring of the lungs that has no known cause. We are also evaluating the potential of a new agent to block the respiratory syncytial virus.

Respiratory

Phase 1
Phase 2
Phase 3

Simtuzumab (monoclonal antibody)
Potential Indication: Idiopathic Pulmonary Fibrosis

GS-5806 (fusion inhibitor)
Potential Indication: Respiratory Syncytial Virus

Gilead is making rapid progress in identifying targeted cancer therapies and evaluating them in clinical studies.  Idelalisib is a small molecule drug designed to inhibit the PI3K delta signaling pathway that drives certain cancer cell development. Momelotinib is an investigational JAK inhibitor that has shown promise for the treatment of myelofibrosis, a blood disorder. Simtuzumab is the first monoclonal antibody developed to target LOXL2, an enzyme involved in solid tumor growth.  Importantly, certain targeted agents may have fewer side effects than conventional treatments such as chemotherapy.

Oncology / Inflammation

Phase 1
Phase 2
Phase 3

Idelalisib (PI3K delta inhibitor)
Potential Indication: Indolent non-Hodgkin’s Lymphoma

U.S. and EU Regulatory Submissions

Idelalisib (PI3K delta inhibitor)
Potential Indication: Chronic Lymphocytic Leukemia

U.S. and EU Regulatory Submissions

Momelotinib (JAK inhibitor)
Potential Indication: Myelofibrosis

Simtuzumab (monoclonal antibody)
Potential Indication: Myelofibrosis

Simtuzumab (monoclonal antibody)
Potential Indication: Pancreatic Cancer

Simtuzumab (monoclonal antibody)
Potential Indication: Colorectal Cancer

GS-9973 (Syk inhibitor)
Potential Indication: Hematological Malignancies

GS-5745 (MMP9 mAb inhibitor)
Potential Indication: Solid Tumors